Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT
A premium complete, integrated service offer for radiopharmaceuticals drug discovery and generation
The process of discovery and development of a molecule is complex, long and costly. Before making a decision on the offer that best meets your needs, we offer online scientific resources and our latest news to help you get to know us better. Our experts are also at your disposal to help and support you in your research and development program.
Filter by BU or service
- All
- Corporate
- Service
- Biotech
- A.I
- Homing program
- Financial
- HR
Filter by BU or service
Filter by category
- All
- Webinar
- Posters
- Scientific publications
- Press release
- Press coverage
- Media kit
- News
Filter by category
Scientific resources
Webinar
Service
07/12/2021
[EN] Preclinical Models for Microbiome Research in Oncology and Inflammatory Diseases
Learn how current in vivo preclinical models meet the needs of microbiome research and innovation while outlining their limitations and the challenges still to be overcome in this growing field.
Service
16/11/2021
[EN] How Rodent and NHP Models Support COVID-19 Treatment Development
Learn how to select the most appropriate COVID-19 animal model for preclinical studies in this webinar
Service
05/11/2021
[EN] Establishing an Expert Network for Your Radiopharmaceutical Drug Development Program
Learn how the DRIVE-MRT solution enables the rationalization, design & optimization of targeted & effective radiopharmaceuticals against specific cancers.
There are no resources available for your request. Contact us directly via our contact form for any information request
Posters
Service
27/09/2021
Structure-Based Design of small macrocyclic CDK9 degraders as chemical biology tools and beyond
With small macrocyclic “probes” from our proprietary library in the low nanomolar range IC50, we turned our attention to CDK9 inhibitors with good selectivity profile against CDK1/2/5/7 as a starting point for building bifunctional small macrocyclic kinase degraders.
Service
Service
26/08/2021
Discovery of Novel Inhibitors of PIM-1 Kinase Enabled by Generative AI
Use generative AI to generate and identify new PIM-1 kinase inhibitor hits with activity, freedom-to-operate, and good in vitro ADME properties.
Service
20/04/2021
Pharmacokinetic and Biodistribution of Formatted Affimer® Biotherapeutics Targeting PD-L1
Programmed Cell Death-Ligand 1 (PD-L1) is part of the immune checkpoint system involved in preventing autoimmunity. PD-L1 is upregulated on tumors cells and binds to its receptor, PD-1, expressed by immune cells in the tumor microenvironment.
Biotech
01/09/2020
NANOCYCLIX® ALK2 INHIBITORS TO OVERCOME CANCER INDUCED ANEMIA
NANOCYCLIX® ALK2 INHIBITORS TO OVERCOME CANCER INDUCED ANEMIA
Biotech
31/03/2019
Nanocyclix: next generation kinase therapeutics A chemocentric approach for the discovery of selective kinase inhibitors
Nanocyclix: next generation kinase therapeuticsA chemocentric approach for the discovery of selective kinase inhibitors
There are no resources available for your request. Contact us directly via our contact form for any information request
Scientific publications
Service
04/09/2021
Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2
SARS-CoV-2; interferon-alpha; nafamostat; antiviral drug combination; broad-spectrum antivirals
Service
04/09/2021
Nafamostat-Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2
SARS-CoV-2; antiviral drug combination; broad-spectrum antivirals; interferon-alpha; nafamostat.
Biotech
12/06/2021
Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors
Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors
Service
19/05/2021
Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
Service
01/04/2021
Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models
Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models
Biotech
07/10/2019
Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells
Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells
Biotech
24/10/2014
In vivo inhibition of RIPK2 kinase alleviates inflammatory disease
In vivo inhibition of RIPK2 kinase alleviates inflammatory disease
There are no resources available for your request. Contact us directly via our contact form for any information request
Press
Press release
Corporate
Financial
05/01/2022
ONCODESIGN announces its 2022 financial agenda
Oncodesign announces all the regulatory dates as far as financial information is concerned. Let's have a look :)
Corporate
Financial
05/01/2022
ONCODESIGN announces its 2022 financial agenda
Oncodesign announces all the regulatory dates as far as financial information is concerned. Let's have a look :)
Biotech
04/11/2021
ONCODESIGN strengthens the intellectual property of ODS 101 in treating inflammatory bowel disease
Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia
Corporate
Financial
25/10/2021
Oncodesign has appointed Karine Lignel as Group Chief Development Officer
Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.
Corporate
Financial
25/10/2021
Oncodesign has appointed Karine Lignel as Group Chief Development Officer
Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.
Biotech
21/10/2021
Oncodesign and TiumBio sign collaboration agreement for R&D of fibrosis drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.
Financial
16/09/2021
Oncodesign announces its results for the first half of 2021
Read all the financial information of Oncodesign and its Business Units Service, Biotech and Artificial Intelligence.
Financial
21/07/2021
Oncodesign announces a sharp increase in turnover in the first half of 2021
Group turnover up by 33% at €15.8M. Despite the global health crisis, which continues to limit international travel...
Corporate
Financial
05/07/2021
Oncodesign announces the appointment of Aline Aubertin as an independent director of the Board of Directors
Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director.
Service
01/07/2021
Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT
Discover the alliance of experts in radiopharmaceuticals: an innovative offer in therapeutic development in nuclear medicine from the validation of therapeutic targets, the generation of radiolabeled biological vectors, the optimization of leads, the generation of drug candidates to IND, the design and management of clinical trials.
Service
Financial
Oncodesign launches its new DRIVE-MRT™ service offer in partnership with Covalab, CheMatech and ABX-CRO
[Press Release] Explore our brand new service offer DRIVE-MRT. it allows the rationalization, design and optimization of targeted radiopharmaceutical products that are effective against certain metastatic cancers.
Biotech
Financial
24/06/2021
Oncodesign provides an update on its progress on RIPK2
[Press Release] Find the update of the RIPK2 program and the start of new programs associated with Nanocyclix.
Biotech
14/06/2021
Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Read Press Release the selection of a preclinical candidate resulting from their strategic collaboration to find new treatments for Parkinson’s disease.
A.I
Financial
18/05/2021
InterSystems & Oncodesign partner for the optimization of data use to enhance and accelerate Drug Discovery processes in oncology
Read PRess Release to have an insight on how to organize & leverage healthcare data to accelerate the search for new treatments in oncology using AI.
Corporate
Service
Service partnership agreement between Oncodesign and Galderma
Press Release: Multi-year service contract: design and discover new drug candidates in dermatology - Galderma.
Corporate
Service
Service partnership agreement between Oncodesign and Galderma
Press Release: Multi-year service contract: design and discover new drug candidates in dermatology - Galderma.
Corporate
Service
Centre Georges François Leclerc Presents the Detailed Results of the First Two Stages of its Clinical Study in Lung Cancer at the EANM Congress
Presentation of detailed results from the first two stages of the clinical trial in lung cancer | 31st EANM1 | 2018.
Corporate
A.I
Precision medicine: Cap Digital and Medicen Paris-Region team-up with Oncodesign, Servier and Intersystems on Hu-PreciMED
Hu-PreciMED project will gear French precision medicine industry towards discovering new diagnostic approaches & novel therapeutic treatments.
There are no resources available for your request. Contact us directly via our contact form for any information request
Press coverage
Financial
Corporate
Biotech
Corporate
Biotech
Corporate
Biotech
Biotech
Corporate
Corporate
There are no resources available for your request. Contact us directly via our contact form for any information request
Media kit
Corporate
There are no resources available for your request. Contact us directly via our contact form for any information request
News
Service
14/01/2022
[Congress] Microbiome Movement Drug Development
Oncodesign will be at the digital event Microbiome Movement Drug Development. Take the opportunity to learn more about SOLO Microbiome.
Corporate
Financial
05/01/2022
ONCODESIGN announces its 2022 financial agenda
Oncodesign announces all the regulatory dates as far as financial information is concerned. Let's have a look :)
Biotech
23/11/2021
Biotech Show Case: looking for partners to pursue the development of our Nanocyclix® technology products together!
Meet Dr. Jan Hoflack during Biotech ShowCase to explore our products pipeline using our technological module Nanocyclix®.
Biotech
04/11/2021
ONCODESIGN strengthens the intellectual property of ODS 101 in treating inflammatory bowel disease
Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia
Corporate
A.I
28/10/2021
Oncodesign: EHDEN Certified SME
EHDEN network will enable transparent & fully reproducible research by standardizing both the health data & the analytical pipeline.
Corporate
Financial
25/10/2021
Oncodesign has appointed Karine Lignel as Group Chief Development Officer
Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.
Biotech
21/10/2021
Oncodesign and TiumBio sign collaboration agreement for R&D of fibrosis drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.
Service
20/10/2021
[WEBINARS] Pharmaco-imaging, COVID-19, Microbiome…
[Webinars] Radiopharmaceutics, COVID-19, Microbiome… join us this fall during a webinar
Service
19/10/2021
[CONGRESS] Discovery UK: 26 – 27 October 2021
Oncodesign will be at the in-person event by Oxford Global in London, Discovery UK.
Financial
16/09/2021
Oncodesign announces its results for the first half of 2021
Read all the financial information of Oncodesign and its Business Units Service, Biotech and Artificial Intelligence.
Corporate
Financial
05/07/2021
Oncodesign announces the appointment of Aline Aubertin as an independent director of the Board of Directors
Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director.
Corporate
02/07/2021
Find out how we built our logo!
Oncodesign Find out how we built our logo! trajectory DNA innovation...green and bleue pharma colors Find out how we built our logo!
Corporate
01/07/2021
Brand new logo for Oncodesign
Brand new logo for Oncodesign. New graphic identity with evolutive look & feel approach... First element of our new logo.
Biotech
Financial
24/06/2021
Oncodesign provides an update on its progress on RIPK2
[Press Release] Find the update of the RIPK2 program and the start of new programs associated with Nanocyclix.
Service
23/06/2021
[Congress] Microbiome movement Drug Development Summit June 29 – July 1, 2021
Listen to our expert talk about “preclinical solutions for microbiome investigation in pathological situation and drug development”
Biotech
14/06/2021
Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Read Press Release the selection of a preclinical candidate resulting from their strategic collaboration to find new treatments for Parkinson’s disease.
A.I
Financial
18/05/2021
InterSystems & Oncodesign partner for the optimization of data use to enhance and accelerate Drug Discovery processes in oncology
Read PRess Release to have an insight on how to organize & leverage healthcare data to accelerate the search for new treatments in oncology using AI.
Service
07/10/2019
[EN] [Congress] Start.Smart.Global 2019 – 7-10 October 2019: Roadshow in Japan & November 2019: Roadshow in South Korea
RoadShow in Japan and South Korean to demonstrate the potency and specificity of our innovative technology module Nanocyclix®
Corporate
Financial
Corporate
Financial
Corporate
Service
Corporate
Financial
Corporate
Our brand Oncodesign
Our brand Oncodesign . Combination of the words oncology and design... Precision Medicine for patient... Oncodesign
There are no resources available for your request. Contact us directly via our contact form for any information request